Propionic Acid

Propionic Acid

SCHEMBL1243152

CCC(=O)O.c1c[nH]nn1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL3625516 1.00 FFAR3 (0.43) FFAR3
Propionic Acid SCHEMBL1242832 0.89 FFAR3 (0.34) FFAR3
Malonic Acid SCHEMBL27973934 0.84 LDHA (0.41)
Glycolic Acid SCHEMBL21635478 0.84
Acetic Acid SCHEMBL9630666 0.84 FFAR3 (0.35) FFAR3
Bicarbonate SCHEMBL5682507 0.84
Bicarbonate SCHEMBL1563325 0.84
Thioglycolic Acid SCHEMBL28058106 0.83
SCHEMBL28860134 0.82 TSHR (0.34)
Acetone SCHEMBL4541424 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222022-B2 Tri-functionalized cryptophane biosensors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2012-07-17 US claimed
US-20100105099-A1 TRI-FUNCTIONALIZED CRYPTOPHANE, SYNTHESIS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-29 US claimed
CN-108137606-A Short-acting benzodiazepine * * derivatives, Its Preparation Method And Use 四川科伦博泰生物医药股份有限公司 2018-06-08 CN disclosed
CN-105820130-A Triazole propionate URAT1 inhibitor, preparation method thereof and purpose of triazole propionate URAT1 inhibitor for treating hyperuricemia and gout 天津药物研究院有限公司 2016-08-03 CN disclosed
EP-2259785-B1 FULLERENE THERAPIES FOR INFLAMMATION LUNA INNOVATIONS INC (US) 2015-12-23 EP disclosed
US-8680125-B2 Fullerene therapies for inflammation LUNA INNOVATIONS INCORPORATED (US) 2014-03-25 US disclosed
US-8563585-B2 2013-10-22 US disclosed
US-8222022-B2 Tri-functionalized cryptophane biosensors THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2012-07-17 US disclosed
US-20110251158-A1 FULLERENE THERAPIES FOR INFLAMMATION AND INHIBITION OF BUILD-UP OF ARTERIAL PLAQUE LUNA INNOVATIONS INCORPORATED (US) 2011-10-13 US disclosed
US-20110028522-A1 FULLERENE THERAPIES FOR INFLAMMATION LUNA INNOVATIONS INCORPORATED (US) 2011-02-03 US disclosed
EP-2259785-A2 FULLERENE THERAPIES FOR INFLAMMATION Luna Innovations Incorporated (US) 2010-12-15 EP disclosed
US-20100105099-A1 TRI-FUNCTIONALIZED CRYPTOPHANE, SYNTHESIS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-29 US disclosed
WO-2009114088-A2 FULLERENE THERAPIES FOR INFLAMMATION LUNA INNOVATIONS INCORPORATED (US) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251158-A1 FULLERENE THERAPIES FOR INFLAMMATION AND INHIBITION OF BUILD-UP OF ARTERIAL PLAQUE IL1B, IL1A, CD68 FFAR3 1983/4885
US-20100105099-A1 TRI-FUNCTIONALIZED CRYPTOPHANE, SYNTHESIS AND USES THEREOF SPR, CACYBP, CRY2 FFAR3 1883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.